These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 9570258)

  • 1. Meta-analysis of somatostatin, octreotide and gabexate mesilate in the therapy of acute pancreatitis.
    Andriulli A; Leandro G; Clemente R; Festa V; Caruso N; Annese V; Lezzi G; Lichino E; Bruno F; Perri F
    Aliment Pharmacol Ther; 1998 Mar; 12(3):237-45. PubMed ID: 9570258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacologic treatment can prevent pancreatic injury after ERCP: a meta-analysis.
    Andriulli A; Leandro G; Niro G; Mangia A; Festa V; Gambassi G; Villani MR; Facciorusso D; Conoscitore P; Spirito F; De Maio G
    Gastrointest Endosc; 2000 Jan; 51(1):1-7. PubMed ID: 10625786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy of somatostatin and its analogues in the treatment of acute pancreatitis: clinical retrospective study].
    Citone G; Perri S; Nardi M; Maira E; Lotti R; Gabbrielli F; Antonellis M; Orsini S
    G Chir; 2001 Apr; 22(4):139-49. PubMed ID: 11370223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Somatostatin, Ulinastatin and Gabexate on the Treatment of Severe Acute Pancreatitis.
    Wang G; Liu Y; Zhou SF; Qiu P; Xu L; Wen P; Wen J; Xiao X
    Am J Med Sci; 2016 May; 351(5):506-12. PubMed ID: 27140710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antisecretory vs. antiproteasic drugs in the prevention of post-ERCP pancreatitis: the evidence-based medicine derived from a meta-analysis study.
    Andriulli A; Caruso N; Quitadamo M; Forlano R; Leandro G; Spirito F; De Maio G
    JOP; 2003 Jan; 4(1):41-8. PubMed ID: 12555015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP: an updated meta-analysis.
    Andriulli A; Leandro G; Federici T; Ippolito A; Forlano R; Iacobellis A; Annese V
    Gastrointest Endosc; 2007 Apr; 65(4):624-32. PubMed ID: 17383459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical trial with a protease inhibitor gabexate mesilate in acute pancreatitis.
    Harada H; Miyake H; Ochi K; Tanaka J; Kimura I
    Int J Pancreatol; 1991; 9():75-9. PubMed ID: 1744450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of octreotide and somatostatin in acute and chronic pancreatitis.
    Uhl W; Anghelacopoulos SE; Friess H; Büchler MW
    Digestion; 1999; 60 Suppl 2():23-31. PubMed ID: 10207228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of gabexate mesilate in acute pancreatitis. A metaanalysis.
    Messori A; Rampazzo R; Scroccaro G; Olivato R; Bassi C; Falconi M; Pederzoli P; Martini N
    Dig Dis Sci; 1995 Apr; 40(4):734-8. PubMed ID: 7720462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: a multicenter, placebo-controlled, randomized clinical trial.
    Andriulli A; Clemente R; Solmi L; Terruzzi V; Suriani R; Sigillito A; Leandro G; Leo P; De Maio G; Perri F
    Gastrointest Endosc; 2002 Oct; 56(4):488-95. PubMed ID: 12297762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of somatostatin and its long-acting analogue, octreotide, in the treatment of pancreatic diseases.
    Delmont J; Hastier P; Dumas R
    Aliment Pharmacol Ther; 1995 Oct; 9(5):581-3. PubMed ID: 8580282
    [No Abstract]   [Full Text] [Related]  

  • 12. [Treatment of acute pancreatitis with protease inhibitor, H2 receptor antagonist and somatostatin analogue].
    Kohsaki T; Nishimori I; Onishi S
    Nihon Rinsho; 2004 Nov; 62(11):2057-62. PubMed ID: 15552889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological approach to acute pancreatitis.
    Bang UC; Semb S; Nojgaard C; Bendtsen F
    World J Gastroenterol; 2008 May; 14(19):2968-76. PubMed ID: 18494044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gabexate mesilate in human acute pancreatitis. German Pancreatitis Study Group.
    Büchler M; Malfertheiner P; Uhl W; Schölmerich J; Stöckmann F; Adler G; Gaus W; Rolle K; Beger HG
    Gastroenterology; 1993 Apr; 104(4):1165-70. PubMed ID: 8462805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Gabexate mesilate in the treatment of acute pancreatitis. Results of a Hannover multicenter double-blind study with 50 patients].
    Freise J; Melzer P; Schmidt FW; Horbach L
    Z Gastroenterol; 1986 Apr; 24(4):200-11. PubMed ID: 3087076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Somatostatin in the treatment of pancreatic diseases].
    Németh AM
    Orv Hetil; 2002 May; 143(19 Suppl):1099-108. PubMed ID: 12063869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conservative treatment of acute pancreatitis: the use of somatostatin.
    Ladas SD; Raptis SA
    Hepatogastroenterology; 1992 Oct; 39(5):466-9. PubMed ID: 1360937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of somatostatin and its analogues in pancreatic surgery and pancreatic disorders.
    Friess H; Büchler MW
    Digestion; 1996; 57 Suppl 1():97-102. PubMed ID: 8813484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gabexate mesilate (FOY) protects against ceruletide-induced acute pancreatitis in the rat.
    Wisner JR; Renner IG; Grendell JH; Niederau C; Ferrell LD
    Pancreas; 1987; 2(2):181-6. PubMed ID: 2442741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential role of somatostatin and octreotide in the management of acute pancreatitis.
    Büchler MW; Binder M; Friess H; Malfertheiner P
    Digestion; 1994; 55 Suppl 1():16-9. PubMed ID: 7907565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.